Scientific
MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis
These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.
MK5 Proteome Network Type I Analysis

Type 1 network in which we propagated the absolute log regulation ratio abs(log(r/g)). We used the filtered lowest boundary of the confidence interval for the microarray measurement based and used the high confidence interaction map. Because type-I networks tend to favour highly connected proteins we tested a normalisation scheme in which we would run the network once with real values (the measured column) and once with simulated values where each measured point is set to 1 instead of the actual signal (the expected column). Afterwards we divided the measured value by the expected value. This normalisation scheme works to a certain extend but will lead to a variance that is directly related to the connectivity of each protein. In the end we dropped the use of Type-I networks due to the many technical problems they pose.
Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene description measured expected final Hugo
Results: HTML CSV LaTeX
Showing element 2458 to 2507 of 3206 in total

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
measured\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
expected\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
final\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2458\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.565608\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.60988\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21671801\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
OXSM\vspace{3pt}}\\\cline{1-1}\cline{3-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2459\vspace{3pt}}&&\parbox{\wcC}{\vspace{3pt}\noindent
0.027214\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.125575\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21671511\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
C20orf80\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2460\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BROMODOMAIN CONTAINING 7; BROMODOMAIN PROTEIN; BROMODOMAIN-CONTAINING 7. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.26631\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.22885\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216714815\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRD7\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2461\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0337015\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.155511\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.216714573\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
RPAP1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2462\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FRG1 PROTEIN (FSHD REGION GENE 1 PROTEIN). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
FRG1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2463\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTIONAL ADAPTOR 3-LIKE ISOFORM A. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
TADA3L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2464\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TRANSCRIPTIONAL ADAPTER 2-LIKE (ADA2-LIKE PROTEIN) (KL04P). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.42132\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.94413\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216713903\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
TADA2L\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2465\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.210228\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.970087\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21671046\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
BRD9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2466\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GALECTIN-4 (LACTOSE-BINDING LECTIN 4) (L-36 LACTOSE BINDING PROTEIN) (L36LBP) (ANTIGEN NY-CO-27). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.384329\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.77366\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216686964\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LGALS4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2467\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RIBONUCLEASE HI LARGE SUBUNIT (EC 3.1.26.-) (RNASE HI LARGE SUBUNIT) (RNASE H(35)) (RIBONUCLEASE H2) (RNASE H2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.321097\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.48248\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21659449\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
RNASEH2A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2468\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
45 KDA CALCIUM-BINDING PROTEIN PRECURSOR (CAB45) (STROMAL CELL-DERIVED FACTOR 4) (SDF-4). \vspace{3pt}}&\multirow{3}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0737619\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.340556\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.216592572\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
SDF4\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2469\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"SPECTRIN BETA CHAIN, BRAIN 4 (SPECTRIN, NON-ERYTHROID BETA CHAIN 4) (BETA-V SPECTRIN) (BSPECV). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
SPTBN5\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2470\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
LSM14B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2471\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BAND 4.1-LIKE PROTEIN 3 (4.1B) (DIFFERENTIALLY EXPRESSED IN ADENOCARCINOMA OF THE LUNG PROTEIN 1) (DAL-1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.115589\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.533671\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216592245\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EPB41L3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2472\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.139984\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.646308\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216590233\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CUEDC2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2473\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PROTEIN 4.1 (BAND 4.1) (P4.1) (EPB4.1) (4.1R). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0900531\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.415778\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216589382\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EPB41\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2474\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BAND 4.1-LIKE PROTEIN 2 (GENERALLY EXPRESSED PROTEIN 4.1) (4.1G). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0915902\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.422875\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216589299\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EPB41L2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2475\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
BAND 4.1-LIKE PROTEIN 1 (NEURONAL PROTEIN 4.1) (4.1N). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0882127\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.407281\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216589284\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
EPB41L1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2476\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0586202\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.270652\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21658883\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LSM14A\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2477\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SIMILAR TO TRNA SYNTHETASE CLASS II. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.205001\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.946559\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216574984\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PARS2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2478\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GALECTIN-9 (HOM-HD-21) (ECALECTIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.522708\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.41413\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216520237\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
LGALS9\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2479\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRE-MRNA CLEAVAGE COMPLEX II PROTEIN PCF11 (FRAGMENT). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.251152\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.15996\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216517811\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PCF11\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2480\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CHROMODOMAIN Y-LIKE PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.549251\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
2.53881\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216341908\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDYL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2481\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TESTIS-SPECIFIC CHROMODOMAIN PROTEIN Y PROTEIN 2. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.659303\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
3.04797\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216308888\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDY2B\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2482\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TESTIS-SPECIFIC CHROMODOMAIN Y PROTEIN 1. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.663776\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
3.06866\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.216308095\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
CDY1B\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2483\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"CHROMODOMAIN PROTEIN, Y CHROMOSOME-LIKE ISOFORM A; CDY-LIKE, AUTOSOMAL; TESTIS-SPECIFIC CHROMODOMAIN Y-LIKE PROTEIN. \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
CDYL\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2484\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HEMK PROTEIN HOMOLOG (EC 2.1.1.-) (M.HSAHEMKP). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.343973\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.59051\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216265852\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HEMK1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2485\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
GLUCOSE-6-PHOSPHATE ISOMERASE (EC 5.3.1.9) (GPI) (PHOSPHOGLUCOSE ISOMERASE) (PGI) (PHOSPHOHEXOSE ISOMERASE) (PHI) (NEUROLEUKIN) (NLK) (SPERM ANTIGEN-36) (SA-36). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.13384\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.618915\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216249404\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GPI\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2486\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CEREBRAL CELL ADHESION MOLECULE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.155588\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.719698\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216185122\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
CEECAM1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2487\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.166202\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.768906\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.21615386\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
GLT25D1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2488\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FIBULIN-2 PRECURSOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.195152\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.90295\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216127139\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
FBLN2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2489\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.194172\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.898593\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.216084479\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2490\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
XPMC2 PREVENTS MITOTIC CATASTROPHE 2 HOMOLOG; XENOPUS PREVENTS MITOTIC CATASTROPHE 2 HOMOLOG. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.172887\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.801332\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215749527\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
REXO4\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2491\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DEHYDRODOLICHYL DIPHOSPHATE SYNTHASE. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.238591\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.10654\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215618956\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
DHDDS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2492\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.239571\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.11109\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215617997\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2493\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SH3-CONTAINING GRB2-LIKE PROTEIN 3 (SH3 DOMAIN PROTEIN 2C) (EEN-B2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.171407\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.795244\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215540136\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SH3GL3\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2494\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
METHIONYL-TRNA SYNTHETASE (EC 6.1.1.10) (METHIONINE--TRNA LIGASE) (METRS). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0641898\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.297931\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.2154519\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
MARS\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2495\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HISTIDINE DECARBOXYLASE (EC 4.1.1.22) (HDC). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0866317\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.402189\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215400471\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
HDC\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2496\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ARMET PROTEIN PRECURSOR (ARGININE-RICH PROTEIN). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.0869714\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.403767\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215399971\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ARMET\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2497\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SH3-CONTAINING GRB2-LIKE PROTEIN 2 (SH3 DOMAIN PROTEIN 2A) (ENDOPHILIN 1) (EEN-B1). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.158519\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.735941\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215396343\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SH3GL2\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2498\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"UBIQUINOL-CYTOCHROME C REDUCTASE COMPLEX CORE PROTEIN I, MITOCHONDRIAL PRECURSOR (EC 1.10.2.2). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.167149\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.776201\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215342418\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
UQCRC1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2499\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"MITOCHONDRIAL PROCESSING PEPTIDASE ALPHA SUBUNIT, MITOCHONDRIAL PRECURSOR (EC 3.4.24.64) (ALPHA-MPP) (P-55) (HA1523). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.235517\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.09378\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215323923\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PMPCA\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2500\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"MITOCHONDRIAL PROCESSING PEPTIDASE BETA SUBUNIT, MITOCHONDRIAL PRECURSOR (EC 3.4.24.64) (BETA-MPP) (P-52). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.208649\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.969013\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215321157\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
PMPCB\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2501\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SH3-CONTAINING GRB2-LIKE PROTEIN 1 (SH3 DOMAIN PROTEIN 2B) (EXTRA ELEVEN-NINETEEN LEUKEMIA FUSION GENE) (EEN) (EEN FUSION PARTNER OF MLL). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.172401\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.800978\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.215238121\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
SH3GL1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2502\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
KERATIN ASSOCIATED PROTEIN 9-4; KERATIN ASSOCIATED PROTEIN 9.4. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
1.02862\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
4.7857\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.214936164\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2503\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
JUNCTIONAL ADHESION MOLECULE 1 PRECURSOR (JAM) (PLATELET ADHESION MOLECULE 1) (PAM-1) (PLATELET F11 RECEPTOR). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.26445\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
1.23096\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.214832326\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
F11R\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2504\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ORNITHINE DECARBOXYLASE ANTIZYME INHIBITOR. \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.174979\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.814661\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.214787501\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
AZIN1\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2505\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ORNITHINE DECARBOXYLASE-LIKE PROTEIN (EC 4.1.1.17) (ODC-PARALOGUE) (ODC-P). \vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
0.177719\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
0.827431\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
0.214784073\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
ADC\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2506\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
"PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY C (WITH FERM DOMAIN) MEMBER 1; MITOGEN INDUCIBLE 2; KINDLIN 2. \vspace{3pt}}&\multirow{2}{*}{\parbox{\wcC}{\vspace{3pt}\noindent
0.0405241\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
0.188688\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
0.214767765\vspace{3pt}}}&\parbox{\wcF}{\vspace{3pt}\noindent
PLEKHC1\vspace{3pt}}\\\cline{1-2}\cline{6-6}
\parbox{\wcA}{\vspace{3pt}\noindent
2507\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ALPHA-PARVIN (CALPONIN-LIKE INTEGRIN-LINKED KINASE BINDING PROTEIN) (CH-ILKBP). \vspace{3pt}}&&&&\parbox{\wcF}{\vspace{3pt}\noindent
\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the bloody hugo identifier as demanded by the BMC Bioinformatics idiots
- http://analysis.yellowcouch.org/